First Tracks Biotherapeutics Secures $200 Million in Institutional Private Placement

Key numbers

Deal value	$200M
Share of market cap	15.5%

Key highlights

• Issuance of 6,106,870 shares of common stock at a price of $32.75 per share
• Total gross proceeds of approximately $200 million before offering expenses
• Participation from institutional investors including TCGX and Affinity Asset Advisors
• Closing of the private placement is scheduled for October 19, 2026
• Proceeds specifically earmarked for the clinical development of CD122 antagonist ANB033

What Is the Capital Raise?

The capital raise is structured as a private placement in public equity (PIPE), involving the sale of 6,106,870 shares of common stock at a fixed price of $32.75 per share. This pricing represents a concentrated investment from a select group of institutional backers, including First Light Asset Management, Sirenia Capital Management, and Trails Edge Capital Partners. The transaction is expected to close on October 19, 2026, subject to standard closing conditions. In conjunction with the raise, First Tracks Biotherapeutics has committed to filing a registration statement with the SEC within 30 days to facilitate the eventual resale of these newly issued shares by the investors.

Use of Proceeds

• Advancement of the clinical development program for ANB033, a CD122 antagonist
• Targeting clinical milestones in celiac disease and eosinophilic esophagitis
• Supporting ongoing development of rosnilimab for rheumatoid arthritis
• Progressing the BDCA2 modulator ANB101 through early-stage trials
• Funding general corporate purposes and essential working capital

Strategic Rationale

This financing arrives as the company prepares for critical clinical milestones, most notably the anticipated top-line Phase 1b data for ANB033 in celiac disease, which is expected in the first quarter of 2027. By securing $200 million now, First Tracks Biotherapeutics significantly extends its operational runway and de-risks the capital requirements needed for these upcoming readouts. The participation of specialized life sciences funds suggests external validation of the company's antibody therapeutic platform. This capital infusion follows a previous $80 million raise in March 2026, indicating an aggressive scaling of research and development activities to meet clinical timelines.

Financial Context

Prior to this capital raise, First Tracks Biotherapeutics maintained a cash runway projected to last into the second quarter of 2028. The addition of $200 million in gross proceeds substantially strengthens the balance sheet of this clinical-stage biotechnology firm, which currently generates no revenue from commercial product sales. The company's stock has shown recent upward momentum, posting a 12.59% gain over the past week, while the Relative Strength Index of 51.3 indicates a neutral technical position. This liquidity event ensures the company remains well-capitalized as it transitions its core programs through late-stage clinical evaluation over the next two years.

Up 0.0% since our story on 15 Oct: $36.04 when we broke it → $36.04 at the close on 15 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

15 Sep	$38.47
16 Sep	$39.00
17 Sep	$39.20
18 Sep	$38.60
21 Sep	$38.99
22 Sep	$41.03
23 Sep	$36.66
24 Sep	$35.83
25 Sep	$34.42
28 Sep	$36.65
29 Sep	$35.98
30 Sep	$35.44
1 Oct	$33.92
2 Oct	$33.28
5 Oct	$32.99
6 Oct	$31.39
7 Oct	$30.59
8 Oct	$32.01
9 Oct	$31.85
12 Oct	$34.05
13 Oct	$31.68
14 Oct	$34.13
15 Oct	$36.04

First Tracks Biotherapeutics, Inc. · financial snapshot

Share price	$36.04
Market cap	$1.3B
1-month price change	-6.32%
Sector	HealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.